Home Cart Sign in  
Chemical Structure| 1346574-57-9 Chemical Structure| 1346574-57-9

Structure of GSK126
CAS No.: 1346574-57-9

Chemical Structure| 1346574-57-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK126 is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, > 1000-fold selective for EZH2 over 20 other human methyltransferases.

Synonyms: GSK2816126A; GSK2816126

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Beitz, Adam M ; Teves, Joji ; Oakes, Conrad G ; Johnstone, Christopher P ; Wang, Nathan B ; Brickman, Joshua M , et al.

Abstract: While transcription factors (TFs) provide essential cues for directing and redirecting cell fate, TFs alone are insufficient to drive cells to adopt alternative fates. Rather, transcription factors rely on receptive cell states to induce novel identities. Cell state emerges from and is shaped by cellular history and the activity of diverse processes. Here, we define the cellular and molecular properties of a highly receptive state amenable to transcription factor-mediated direct conversion from fibroblasts to induced motor neurons. Using a well-defined model of direct conversion to a postmitotic fate, we identify the highly proliferative, receptive state that transiently emerges during conversion. Through examining chromatin accessibility, histone marks, and nuclear features, we find that cells reprogram from a state characterized by global reductions in nuclear size and transcriptional activity. Supported by globally increased levels of H3K27me3, cells enter a quiescent-like state of reduced RNA metabolism and elevated expression of REST and p27, markers of quiescent neural stem cells. From this transient state, cells convert to neurons at high rates. Inhibition of Ezh2, the catalytic subunit of PRC2 that deposits H3K27me3, abolishes conversion. Our work offers a roadmap to identify global changes in cellular processes that define cells with different conversion potentials that may generalize to other cell-fate transitions.

Purchased from AmBeed:

Alternative Products

Product Details of GSK126

CAS No. :1346574-57-9
Formula : C31H38N6O2
M.W : 526.67
SMILES Code : O=C(C1=CC(C2=CC=C(N3CCNCC3)N=C2)=CC4=C1C(C)=CN4[C@@H](C)CC)NCC5=C(C)C=C(C)NC5=O
Synonyms :
GSK2816126A; GSK2816126
MDL No. :MFCD23381067
InChI Key :FKSFKBQGSFSOSM-QFIPXVFZSA-N
Pubchem ID :68210102

Safety of GSK126

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280-P305+P351+P338

Related Pathways of GSK126

epigenetics

Isoform Comparison

Biological Activity

Target
  • Histone Methyltransferase

    EZH2, IC50:9.9 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
RMG1 cells 100 nM 12 days GSK126 selectively inhibits the growth of ARID1A knockdown cells, significantly reducing cell growth compared to controls. PMC4352133
OVISE cells 5 μM 12 days GSK126 significantly reduces 3D growth of ARID1A mutated cells, while the effects on ARID1A wild type cells are not significant. PMC4352133
Primary hepatocytes 5 μM 48 h GSK126 reversed the effects of HBx on D-GalN-induced ferroptosis in hepatocytes, leading to a rebound in SLC7A11 expression and improved cell viability, MDA, GSH, and iron levels. PMC8495979
BT12 cells 6 μM 72 h To evaluate the effect of GSK126 on cell proliferation, the results showed that GSK126 significantly inhibited the metabolic activity of BT12 cells. PMC9081147
NUH40 cells 6 μM 72 h To evaluate the effect of GSK126 on cell proliferation, the results showed that GSK126 significantly inhibited the metabolic activity of NUH40 cells. PMC9081147
Kelly cells 5 μM 48 h GSK126 inhibited EZH2 methyltransferase activity but had minimal effects on MYCN expression PMC8748958
NCI-H82 cells 5 μM 48 h GSK126 partially reduced MYC expression and inhibited cell proliferation PMC8748958
DLBCL cell lines 4 μM 4 days To investigate the effect of GSK126 on MHC-I expression, results showed that GSK126 treatment significantly increased HLA-B and NLRC5 transcription PMC7874576
KB1P-G3 7.5 µM 72 h Single agent GSK126 treatment induced 17% reduction of viability, while the combination with AZD1390 displayed 93% cytotoxicity in BRCA1-deficient cells. PMC9206299
KB1P-B11 7.5 µM 72 h Single agent GSK126 treatment induced 17% reduction of viability, while the combination with AZD1390 displayed 93% cytotoxicity in BRCA1-deficient cells. PMC9206299
SUM149 7.5 µM 72 h Single agent GSK126 treatment induced 17% reduction of viability, while the combination with AZD1390 displayed 77-79% cytotoxicity in BRCA1-mutant cells. PMC9206299
GES-1 cells 2 µM 72 h Inhibited H3K27me3 methylation, reduced RPL15 expression, and attenuated Wnt signaling pathway PMC11328474
A549 cells 5 µM 11 days By inhibiting EZH2, GSK126 moderately activated the reporter in A549 cells, indicating it promoted partial activation of EMT. PMC7904264
H1944 cells 5 µM 11 days By inhibiting EZH2, GSK126 moderately activated the reporter in H1944 cells, indicating it promoted partial activation of EMT. PMC7904264

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Immunocompromised mice ARID1A mutated ovarian cancer model Intraperitoneal injection 50 mg/kg Daily for 3 weeks GSK126 treatment causes regression of ARID1A mutated tumors and significantly reduces the number of tumor nodules in the peritoneal cavity. PMC4352133
C57BL/6 mice LPS/D-GalN-induced acute liver failure model Intraperitoneal injection 150 mg/kg Single dose, continued until the end of the experiment GSK126 partially reversed the effects of HBx on LPS/D-GalN-induced acute liver failure and ferroptosis, improving liver histopathology, MDA, GSH, and iron levels. PMC8495979
Athymic mice Intracranial AT/RT xenograft model Intraperitoneal injection 100 mg/kg Once daily for 20 days To evaluate the anti-tumor effect of GSK126 in intracranial AT/RT xenograft models, the results showed that GSK126 monotherapy significantly inhibited tumor growth and prolonged the survival of mice. PMC9081147
mice Kelly xenograft model intraperitoneal injection 25 mg/kg, 50 mg/kg, 100 mg/kg once daily for 2 weeks GSK126 at 25 mg/kg significantly inhibited H3K27me3 but had minimal effects on MYCN expression and tumor growth PMC8748958
mice BRCA1-deficient mammary tumor model intraperitoneal injection (GSK126), oral gavage (AZD1390) 150 mg/kg daily for 28 consecutive days Combined treatment with GSK126 and AZD1390 significantly increased anti-tumor activity and prolonged progression-free survival in BRCA1-deficient mammary tumor-bearing mice. PMC9206299

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02082977 Cancer|Neoplasms PHASE1 TERMINATED 2017-06-20 GSK Investigational Site, Chic... More >>ago, Illinois, 60611, United States|GSK Investigational Site, New York, New York, 10021, United States|GSK Investigational Site, Villejuif cedex, 94805, France|GSK Investigational Site, Sutton, Surrey, SM2 5PT, United Kingdom|GSK Investigational Site, Southampton, SO16 6YD, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.49mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

References

 

Historical Records

Categories